Earnings summaries and quarterly performance for GILEAD SCIENCES.
Executive leadership at GILEAD SCIENCES.
Daniel P. O’Day
Detailed
Chairman and Chief Executive Officer
CEO
AD
Andrew D. Dickinson
Detailed
Chief Financial Officer
DH
Deborah H. Telman
Detailed
Executive Vice President, Corporate Affairs and General Counsel
DB
Dietmar Berger
Detailed
Chief Medical Officer
EB
Erin Burkhart
Detailed
Senior Vice President, Controllership and Principal Accounting Officer
JM
Johanna Mercier
Detailed
Chief Commercial Officer
Board of directors at GILEAD SCIENCES.
Research analysts who have asked questions during GILEAD SCIENCES earnings calls.
TV
Tyler Van Buren
TD Cowen
7 questions for GILD
Also covers: ADVM, ALLO, ARQT +12 more
CB
Courtney Breen
AllianceBernstein
6 questions for GILD
Also covers: ABBV, AMGN, BMY +4 more
UR
Umer Raffat
Evercore ISI
6 questions for GILD
Also covers: ALKS, AMGN, BHC +15 more
Brian Abrahams
RBC Capital Markets
5 questions for GILD
Also covers: ACAD, ATAI, BCRX +18 more
Daina Graybosch
Leerink Partners
5 questions for GILD
Also covers: AFMD, BNTX, CGEN +6 more
Geoff Meacham
Citigroup Inc.
5 questions for GILD
Also covers: ABBV, AMGN, BMY +9 more
Michael Yee
Jefferies
5 questions for GILD
Also covers: ABBV, ALLO, AMGN +18 more
CL
Carter L. Gould
Barclays
4 questions for GILD
Also covers: ABBV, ALEC, AMGN +7 more
CS
Christopher Schott
JPMorgan Chase & Co.
4 questions for GILD
Also covers: ABBV, AMGN, AMRX +15 more
Mohit Bansal
Wells Fargo & Company
4 questions for GILD
Also covers: ABBV, AMGN, BMRN +16 more
Terence Flynn
Morgan Stanley
4 questions for GILD
Also covers: ABBV, AMGN, ARVN +17 more
ES
Evan Seigerman
BMO Capital Markets
3 questions for GILD
Also covers: ABBV, AMGN, ARVN +15 more
CS
Chris Schott
JPMorgan Chase & Company
2 questions for GILD
Also covers: ABBV, AMGN, BIIB +8 more
LC
Louise Chen
Cantor Fitzgerald
2 questions for GILD
Also covers: AMGN, ARDX, CNTB +17 more
Matthew Biegler
Oppenheimer & Co. Inc.
2 questions for GILD
Also covers: ALLO, ARVN, CTMX +2 more
Salveen Richter
Goldman Sachs
2 questions for GILD
Also covers: ACAD, AGIO, ALLO +20 more
TA
Tazeen Ahmad
Bank of America
2 questions for GILD
Also covers: ACAD, ALNY, APLS +22 more
TA
Timothy Anderson
BofA Securities
2 questions for GILD
Also covers: ABBV, AMGN, AZN +10 more
AH
Alexandria Hammond
Wolfe Research
1 question for GILD
Also covers: ABBV, AMGN, BIIB +7 more
C
Chris
Morgan Stanley
1 question for GILD
Also covers: MRNA, REGN, VRTX
EM
Eliana Merle
UBS
1 question for GILD
Also covers: ALNY, APLS, ARVN +17 more
Geoffrey Meacham
Citi
1 question for GILD
Also covers: ABBV, BIIB, BMY +6 more
JS
James Shin
Analyst
1 question for GILD
Also covers: ABBV, AMGN, AUTL +7 more
NG
Nicole Germino
Truist Securities
1 question for GILD
Also covers: CRIS, INSM, SGMO +1 more
Sadia
Wells Fargo & Company
1 question for GILD
SB
Simon Baker
Redburn Atlantic
1 question for GILD
Also covers: AUTL, AZN, BNTX +5 more
Recent press releases and 8-K filings for GILD.
Gilead Sciences reports strong Q4 and issues 2026 guidance
GILD
Earnings
Guidance Update
- Gilead ended 2025 with $28.9 billion in product sales and a 6% year-over-year HIV sales increase, driven by Biktarvy’s $4.0 billion and Descovy’s $819 million in Q4.
- The newly launched HIV-prevention injection Yeztugo posted $96 million in Q4 and is forecast for $800 million in 2026, below some investor expectations.
- Q4 cash metrics included $10.6 billion in cash and equivalents, $3.3 billion in operating cash flow, $1.0 billion in dividends paid and $230 million in share repurchases.
- For 2026, Gilead expects $29.6 billion–$30.0 billion in product sales and $8.45–$8.85 in non-GAAP EPS.
- Upcoming 2026 pipeline milestones span Phase 3 readouts and launches for Trodelvy P3 EVOKE-03, ASCENT-GYN, BIC/LEN, ISL/LEN and anito-cel in 2H26, plus an FDA decision on bulevirtide in 1H26.
3 days ago
Gilead Sciences reports Q4 2025 results and 2026 guidance
GILD
Earnings
Guidance Update
Product Launch
- Full-year 2025 total product sales were $28.9 billion (up 1% vs. 2024), with base business revenue of $28 billion (+4%), driven by 6% HIV sales growth to $20.8 billion; non-GAAP diluted EPS was $8.15.
- Q4 2025 product sales reached $7.9 billion (+5% YoY; +7% ex-Veklury), and non-GAAP EPS was $1.86.
- 2026 guidance: total product sales of $29.6 billion–$30 billion; base business up 4–5%; HIV sales +6% (Yeztugo revenue ~ $800 million); cell therapy revenues down ~ 10%.
- Pipeline and launches: four planned 2026 commercial launches—Trodelvy in first-line metastatic TNBC, daily oral bictegravir + lenacapavir for HIV, anito-cel in multiple myeloma, and bulevirtide for hepatitis D—and 53 ongoing clinical programs with five pivotal readouts expected in 2026.
4 days ago
Gilead Sciences reports Q4 2025 results
GILD
Earnings
Guidance Update
Product Launch
- Gilead delivered Q4 total product sales of $7.9 B, up 5% YoY (base business $7.7 B, +7% YoY), driven by HIV ($5.8 B, +6% YoY) and Liver Disease ($844 M, +17% YoY).
- For FY25, base business sales reached $28.0 B, +4% YoY (+8% ex-Part D redesign), with total product sales of $28.9 B, +1% YoY (+5% ex-Part D redesign).
- Q4 non-GAAP diluted EPS was $1.86, down 2% YoY, and non-GAAP operating income was $3.09 B, down 1% YoY.
- FY26 guidance projects total product sales of $29.6–30.0 B and non-GAAP diluted EPS of $8.45–8.85.
- Key 2026 milestones include Phase 3 updates for ISLEND-1/-2 in 1H26 and multiple FDA decisions—BIC/LEN, ASCENT-03/04, EVOKE-03—in 2H26, supporting future growth.
4 days ago
Gilead Sciences reports Q4 2025 results
GILD
Earnings
Guidance Update
Product Launch
- Q4 2025 total product sales were $7.9 billion (+5% YoY; ex-Veklury $7.7 billion, +7% YoY), and full-year 2025 sales were $28.9 billion (+1% YoY; base business ex-Veklury $28 billion, +4% YoY)
- 2025 HIV sales reached $20.8 billion, up 6% YoY (10% YoY ex–Medicare Part D headwind), with Q4 HIV revenue of $5.8 billion, +6% YoY
- Gilead plans four new commercial launches in 2026 and up to 10 by 2027 across HIV, oncology, and liver disease (e.g., Trodelvy first-line metastatic TNBC, bictegravir + lenacapavir oral combo, Anito-cel, bulevirtide), supported by five Phase III readouts
- 2026 guidance targets $29.6 – 30 billion in total product sales, $29 – 29.4 billion in base business sales (+4 – 5% YoY), and non-GAAP diluted EPS of $8.45 – 8.85 per share
4 days ago
Gilead Sciences reports Q4 2025 results
GILD
Earnings
Guidance Update
- FY2025 product sales were $28.9 billion, up 1% YoY; base business revenue was $28 billion, up 4%, after $1.1 billion Part D and $900 million Veklury headwinds.
- Full-year segment sales: HIV $20.8 billion (+6%), liver $3.2 billion (+6%), Veklury $911 million (–49%).
- Q4 2025 product sales reached $7.9 billion (+5% YoY; +7% ex-Veklury) and non-GAAP EPS was $1.86 vs $1.90 a year ago.
- 2026 guidance: total product sales $29.6–30 billion; base business $29–29.4 billion (+4–5%); non-GAAP EPS $8.45–8.85.
- HIV & prevention outlook: 2026 HIV sales expected +6% (–2% policy headwinds) ; Sunlenca revenue ~$800 million (vs $150 million in 2025) ; Yes2Go revenue ~$800 million.
4 days ago
Gilead Sciences announces Q4 and full‐year 2025 financial results
GILD
Earnings
Guidance Update
Dividends
- Q4 2025 revenues rose 5% to $7.9 B, with diluted EPS of $1.74 (vs. $1.42 in Q4 2024)
- Full-year 2025 revenues increased 2% to $29.4 B, delivering diluted EPS of $6.78 (vs. $0.38 in 2024)
- Product sales excluding Veklury grew 4% to $28.0 B for FY 2025, led by Biktarvy sales up 7% to $14.3 B
- Generated $3.3 B of operating cash flow in Q4, held $10.6 B in cash and marketable securities at year-end, and returned capital via $1.0 B of dividends and $230 M of share repurchases in Q4 2025
- For 2026, expects product sales of $29.6–30.0 B, diluted EPS of $6.75–7.15, and non-GAAP EPS of $8.45–8.85
4 days ago
Gilead Sciences reports Q4 and FY 2025 results
GILD
Earnings
Dividends
Share Buyback
- Q4 2025 revenue rose 5% to $7.9 billion; diluted EPS was $1.74, up from $1.42 in Q4 2024.
- Full-year 2025 revenue increased 2% to $29.4 billion, with product sales up 1% to $28.9 billion; diluted EPS surged to $6.78 from $0.38 in 2024.
- Ended 2025 with $10.6 billion in cash and equivalents; Q4 operating cash flow was $3.3 billion, while $1.0 billion was returned in dividends and $230 million in share repurchases.
4 days ago
Gilead Sciences updates Yescarta label for R/R central nervous system lymphoma
GILD
- The FDA approved an updated prescribing label for Kite’s Yescarta® removing prior limitations of use for relapsed/refractory primary central nervous system lymphoma (PCNSL), making it the only CAR T-cell therapy for R/R large B-cell lymphoma without this restriction.
- This decision is based on a Phase 1 investigator-sponsored study at Dana-Farber demonstrating a manageable safety profile with no new safety signals in PCNSL patients.
- In the study of 13 PCNSL patients, neurologic toxicities occurred in 85% (11/13) of patients, with 31% (4/13) experiencing Grade 3 events, reinforcing the expanded label indication.
8 days ago
Gilead Sciences publishes Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line PD-L1+ metastatic TNBC
GILD
- The New England Journal of Medicine published full Phase 3 ASCENT-04/KEYNOTE-D19 data showing Trodelvy (sacituzumab govitecan) plus Keytruda reduced the risk of progression or death by 35% (HR 0.65; p<0.001), with median PFS of 11.2 vs. 7.8 months versus Keytruda plus chemotherapy.
- The global, randomized study enrolled 443 previously untreated PD-L1+ metastatic TNBC patients (1:1 randomization) and met its primary endpoint of BICR-assessed PFS using RECIST v1.1.
- Safety was consistent with known profiles: in the Trodelvy-Keytruda arm, the most frequent grade ≥3 treatment-emergent adverse events were neutropenia (43%) and diarrhea (10%), and discontinuations were lower at 12% vs. 31% with Keytruda plus chemotherapy.
- Based on these results, Gilead has submitted supplemental applications for first-line PD-L1+ metastatic TNBC to the FDA and EMA.
Jan 21, 2026, 10:00 PM
Gilead details pipeline and financial strategy at JPMorgan Healthcare Conference
GILD
Product Launch
Dividends
Share Buyback
- Gilead’s HIV business grew 7% through Q3 2025 despite a $900 million Medicare Part D headwind; Lenacapavir (Sunlenca) launch achieved over 80% U.S. payer coverage (≈90% $0 copay) and was delivered in sub-Saharan Africa in 2025, while Biktarvy’s patent expiry is now extended to 2033.
- The company expects up to 10 new medicines or indications by end-2027, with key upcoming milestones including an FDA decision on once-daily Bictegravir/Lenacapavir in H2 2026 and a Phase 1 update on once-every-six-months INSTI GS-3242 this quarter.
- In oncology, Trodelvy is positioned for a first-line triple-negative breast cancer launch in 2026, and Anito-cel has been filed for fourth-line multiple myeloma with a targeted H2 2026 launch; the iMMagine-3 second-line study may support a 2027 filing.
- Financial discipline drives a 50% operating margin in Q3 2025 (top quartile of peers); since 2020, Gilead has paid $22 billion in dividends, commits to returning ≥50% of free cash flow annually, and has enacted opportunistic share repurchases.
Jan 12, 2026, 7:15 PM
Quarterly earnings call transcripts for GILEAD SCIENCES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more